Skip to main content
OpenTrials
Completed

NCT Number: NCT03310645

Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients

To investigate the safety and tolerability of ascending repeated oral doses of BAY1817080 in healthy volunteers(Part1).

To investigate the safety, tolerability and efficacy of BAY1817080 in patients with refractory chronic cough(Part2).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cough Chronic Cough Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Tract Diseases Signs and Symptoms Signs and Symptoms, Respiratory

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

North Tyneside General Hospital, North Shields, Tyne and Wear, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Part 1

  • Male; healthy according to complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), 12 lead ECG, clinical laboratory tests
  • Age: 18-45 years (inclusive) at the first screening visit.
  • Non-smoker for at least the past 6 months and with a pack year history of equal to or less than 5 years.
  • Subjects who are sexually active and have not been surgically sterilized must agree to use two reliable and acceptable methods of contraception simultaneously when having sexual intercourse with women of childbearing potential (one method used by the subject and one method used by the partner) during the study and for 90 days after receiving the investigational medicinal product and not to act as sperm donor for 90 days after dosing. [Acceptable methods of contraception include for example: (a) condoms (male or female) with or without a spermicidal agent, (b) diaphragm or cervical cap with spermicide, (c) intrauterine device, (d) hormone-based contraception.

Part 2:

  • Age: >18 years at the first screening visit
  • Refractory chronic cough for at least one year:
  • that has been shown to be unresponsive to at least 8 weeks of targeted treatment for identified underlying triggers including reflux disease, asthma and post-nasal drip or unexplained cough, and
  • for which no objective evidence of an underlying trigger can be determined after investigation.
  • Score of >40 mm on the Cough Severity visual analogue scale (VAS) at screening.
  • For male patients:

Male patients who are sexually active and have not been surgically sterilized must agree to use two reliable and acceptable methods of contraception simultaneously (one method used by the study patient and one method used by the partner) during the study and for 90 days after receiving the investigational medicinal product and not to act as sperm donor for 90 days after dosing. [Acceptable methods of contraception include for example: (a) condoms (male or female) with or without a spermicidal agent, (b) diaphragm or cervical cap with spermicide, (c) intrauterine device, (d) hormone-based contraception.

--For female patients: Confirmed post-menopausal woman (defined as exhibiting spontaneous amenorrhea for at least 12 months before screening or as exhibiting spontaneous amenorrhea for 6 months before screening with documented serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL) or Woman without childbearing potential based on surgical treatment at least 6 weeks before screening such as bilateral tubal ligation, bilateral oophorectomy with or without hysterectomy (documented by medical report verification) or Woman of childbearing potential that agrees to use two reliable and acceptable methods of contraception simultaneously (one method used by the study patient and one method used by the partner) during the study and for at least 10 days after the last dose. Acceptable methods of contraception include for example: (a)condoms (male or female) with or without a spermicidal agent (b)diaphragm or cervical cap with spermicide (c) intrauterine device (d)hormone-based contraception.

Exclusion criteria

Part 1

  • Relevant diseases potentially interfering with the study's aims (e.g.respiratory diseases) within the four weeks before screening or between screening and randomization
  • Any febrile illness within the four weeks before screening or between screening and randomization
  • Medical history of hypogeusia/dysgeusia or the subject has a dysfunction in his/her ability to taste, as revealed by the taste disturbance questionnaire during screening and the pre dose procedures
  • Use of any over-the-counter cough mixture within the 24 hours before screening

Part 2:

  • FEV1 or FVC of less than 60% of predicted normal, at screening
  • History of upper or lower respiratory tract infection or recent significant change in pulmonary status within the 4 weeks before baseline visit.
  • Current smoking habit or history of smoking within the 6 months before the screening visit.
  • History of smoking (at any time) for more than 20 pack-years in total (20 cigarettes per pack)

Treatment and study plan

BAY1817080

Drug

4 different doses over the course of study

Matching Placebo

Drug

Matching placebo for BAY1817080

Primary outcomes

  1. Frequency of treatment emergent adverse events in study part 1

    Time frame: Up to 5 weeks

  2. Severity of treatment emergent adverse events in study 1

    Time frame: Up to 5 weeks

    The intensity of an AE is classified according to the following categories:

    • Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.
    • Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant.
    • Severe: A type of adverse event that requires intensive therapeutic intervention. The event interrupts usual activities of daily living, or significantly affects clinical status

  3. Frequency of treatment emergent adverse events in study part 2

    Time frame: Up to 12 weeks

  4. Severity of treatment emergent adverse events in study part 2

    Time frame: Up to 12 weeks

    The intensity of an AE is classified according to the following categories:

    • Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.
    • Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant.
    • Severe: A type of adverse event that requires intensive therapeutic intervention. The event interrupts usual activities of daily living, or significantly affects clinical status

  5. 24-hour cough counts

    Time frame: At week 1 in period A

  6. 24 hour cough counts

    Time frame: At week 2 in period A

  7. 24 hour cough counts

    Time frame: At week 3 in period A

  8. 24 hour cough counts

    Time frame: At week 1 in period B

  9. 24 hour cough counts

    Time frame: At week 2 in period B

  10. 24 hour cough counts

    Time frame: At week 3 in period B

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Two-part, Double-blind, Placebo-controlled, Randomized, Parallel-group Study: (Part 1) in Healthy Male Volunteers to Assess Safety and Tolerability of Ascending Repeated Oral Doses of BAY1817080, Followed by (Part 2), Two-way Crossover Administration of Four Different Doses in Patients With Refractory Chronic Cough to Assess Safety, Tolerability and Efficacy for Proof of Concept

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Oct 16, 2017
Registry last updated
Jan 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.